TROVAGENE INC. established the Trovagene Research Institute, a European subsidiary focused on expanding the capabilities and adoption of the company’s Precision Cancer Monitoring platform. Trovagene has also entered into a collaboration with the Department of Oncology at the University of Torino.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
